The estimated Net Worth of Elizabeth Trehu is at least $1.12 million dollars as of 9 January 2023. Elizabeth Trehu owns over 9,285 units of Jounce Therapeutics Inc stock worth over $194,424 and over the last 7 years he sold JNCE stock worth over $144,497. In addition, he makes $777,673 as Chief Medical Officer at Jounce Therapeutics Inc.
Elizabeth has made over 11 trades of the Jounce Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 9,285 units of JNCE stock worth $10,306 on 9 January 2023.
The largest trade he's ever made was exercising 24,875 units of Jounce Therapeutics Inc stock on 8 June 2018 worth over $99,998. On average, Elizabeth trades about 3,822 units every 81 days since 2018. As of 9 January 2023 he still owns at least 103,417 units of Jounce Therapeutics Inc stock.
You can see the complete history of Elizabeth Trehu stock trades at the bottom of the page.
Dr. Elizabeth G. Trehu M.D. serves as Chief Medical Officer of the Company. Dr. Trehu joined Jounce as our chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.
As the Chief Medical Officer of Jounce Therapeutics Inc, the total compensation of Elizabeth Trehu at Jounce Therapeutics Inc is $777,673. There are 4 executives at Jounce Therapeutics Inc getting paid more, with Kimberlee Drapkin having the highest compensation of $2,032,250.
Elizabeth Trehu is 59, he's been the Chief Medical Officer of Jounce Therapeutics Inc since 2015. There are 8 older and 7 younger executives at Jounce Therapeutics Inc. The oldest executive at Jounce Therapeutics Inc is Dr. Louis M. Weiner M.D., 69, who is the Founder.
Elizabeth's mailing address filed with the SEC is C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 8 years, insiders at Jounce Therapeutics Inc have traded over $39,574,093 worth of Jounce Therapeutics Inc stock and bought 724,587 units worth $10,288,083 . The most active insiders traders include Kevin Ctang Capital Managem..., Harbor Master Investors (Ca... et Rock Ventures Ii, L.P.Third.... On average, Jounce Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $171,610. The most recent stock trade was executed by Richard /Ca/ Murray on 4 April 2023, trading 39,228 units of JNCE stock currently worth $72,572.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
Jounce Therapeutics Inc executives and other stock owners filed with the SEC include: